
MDAI Stock Forecast & Price Target
MDAI Analyst Ratings
Bulls say
Spectral AI Inc is projected to experience substantial revenue growth, with expectations of reaching a compound annual growth rate (CAGR) of over 69% from FY26 through FY30 following the commercial launch of its DeepView System. The company's revenue expectations have notably been adjusted to $18.5 million for FY26, indicating a significant increase from prior estimates, reflecting a heightened confidence in its research and development efforts. Additionally, Spectral AI's license model is anticipated to foster recurring revenue at high margins, positioning the company for stable and predictive growth within the MedTech industry.
Bears say
Spectral AI Inc has revised its fiscal year 2025 revenue guidance significantly downward, projecting approximately $18.5 million in revenue, which represents a year-over-year decline of 37.6% compared to earlier estimates. This reduction in expected revenue is attributed to delays associated with the timing of work under the BARDA contract and the impacts of a government shutdown, leading to concerns about the company's operational efficiency. Additionally, a lack of specific revenue guidance for fiscal year 2026, coupled with anticipations of further declines due to extended clinical and regulatory development timelines, exacerbates the uncertainty surrounding the company's financial outlook.
This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.
MDAI Analyst Forecast & Price Prediction
Start investing in MDAI
Order type
Buy in
Order amount
Est. shares
0 shares